



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

August 13, 2021

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

BSE Script Code: 531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

NSE Symbol: FDC

Sub: Press Release

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

**Varsharani Katre
Company Secretary
F-8948**



v



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

FDC Limited reports Q1 FY22 results

Mumbai, 12th August, 2021: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the first quarter ending 30th June, 2021.

Consolidated Q1 FY22 FDC reported

Rs. in crores	Q1' 21-22	Q1' 20-21	YOY Growth
Operating Revenues	447.47	308.18	45.20%
EBITDA	138.67	131.55	5.41%
EBITDA %	29.46%	39.13%	-24.71%
PBT	128.30	121.36	5.72%
PAT	97.84	91.72	6.67%
EPS	5.80	5.36	8.21%

Commenting on the results;

We have had a good start to the financial year with a strong growth in our Domestic business, which is a big pie of our overall business. This was driven by robust demand across our established therapies and brands leading to 68% revenue growth. Our USA business portfolio saw some price erosion laid by re-entry of competitors, still our partner have been successful in maintaining good portion of market share.

The Company has been able to maintain a healthy EBITDA margin and has steadily increased over the past few years. The EBITDA margin for the quarter ended June 30, 2021 is not comparable with previous year quarter ended June 30, 2020, as during that period, certain operating expenses such as sales & marketing, travel and other plant overheads were not incurred due to Covid outbreak.

India Market:

Sale of branded formulations in India for Q1 FY22 was Rs. 388.47 crores, a healthy growth of 68% on YoY and 66% on QoQ. Overall sales in India market accounted for 87.24% of total consolidated sales for the quarter.

As per secondary sales data by IQVIA for the quarter ended June 30, 2021, the Company delivered a strong YoY growth of 44% compared to Indian Pharmaceutical Market (IPM) growth of 39% YoY. This growth was mainly driven by big brands like Zifi, Electral and Enerzal which witnessed a good volume growth partly helped by higher COVID-19 cases during the quarter.



CORPORATE OFFICE

: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE

: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

Export Formulations Market:

Formulation Sales in the Export market were Rs. 43.12 crores in Q1 FY22, down by 27% over YoY and down by 25% QoQ and accounted for 9.65% of total consolidated sales.

The main contributor is the USA market, accounting to 44.83% of total Export Formulations Sales.

Export API Market:

API Sales in the Export market were Rs. 13.89 crores in Q1 FY22, down by 9% over YoY and down 27% QoQ and accounted for 3.11% of total consolidated sales.

ABOUT FDC LTD

Established in 1940, with the dream of building a world class company and vision to make the nation self-reliant in healthcare. FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmics. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs), Finished Dosage Forms and Functional foods & Nutraceuticals. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life to millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

